Filipe B Rodrigues
Overview
Explore the profile of Filipe B Rodrigues including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1042
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anderson D, Ferreira-Correia A, Rodrigues F, Byrne L, Wild E, Krause A
J Huntingtons Dis
. 2025 Feb;
14(1):103-108.
PMID: 39973395
Huntington's disease-like 2 (HDL2) closely resembles Huntington's disease (HD) in clinical and pathological features. Neurofilament light chain (NfL) is an important biomarker in HD research and holds potential in HDL2....
2.
Maiuri T, Bazan C, Harding R, Begeja N, Kam T, Byrne L, et al.
Proc Natl Acad Sci U S A
. 2024 Sep;
121(40):e2318098121.
PMID: 39331414
Huntington disease (HD) is a genetic neurodegenerative disease caused by cytosine, adenine, guanine (CAG) expansion in the () gene, translating to an expanded polyglutamine tract in the HTT protein. Age...
3.
Lowe A, Rodrigues F, Arridge M, De Vita E, Johnson E, Scahill R, et al.
Brain Commun
. 2022 Nov;
4(6):fcac258.
PMID: 36382217
Proton magnetic resonance spectroscopy is a non-invasive method of exploring cerebral metabolism. In Huntington's disease, altered proton magnetic resonance spectroscopy-determined concentrations of several metabolites have been described; however, findings are...
4.
Rodrigues F, Ferreira J, Costa J, Sampaio C
Mov Disord
. 2022 Jul;
37(7):1567-1568.
PMID: 35856730
No abstract available.
5.
Lipsmeier F, Simillion C, Bamdadian A, Tortelli R, Byrne L, Zhang Y, et al.
J Med Internet Res
. 2022 Jun;
24(6):e32997.
PMID: 35763342
Background: Remote monitoring of Huntington disease (HD) signs and symptoms using digital technologies may enhance early clinical diagnosis and tracking of disease progression, guide treatment decisions, and monitor response to...
6.
Estevez-Fraga C, Rodrigues F, Tabrizi S, Wild E
J Huntingtons Dis
. 2022 May;
11(2):105-118.
PMID: 35570498
In this edition of the Huntington's Disease Clinical Trials Corner we expand on GENERATION HD1, PRECISION-HD1 and PRECISION-HD2, SELECT-HD, and VIBRANT-HD trials, and list all currently registered and ongoing clinical...
7.
Furby H, Siadimas A, Rutten-Jacobs L, Rodrigues F, Wild E
Eur J Neurol
. 2022 May;
29(8):2249-2257.
PMID: 35514071
Background: Huntington's disease (HD) is a rare neurodegenerative disease that presents with progressive psychological, cognitive and motor impairment. These diverse symptoms place a high burden on the patient, families and...
8.
Byrne L, Schultz J, Rodrigues F, van der Plas E, Langbehn D, Nopoulos P, et al.
Mov Disord
. 2022 Apr;
37(7):1526-1531.
PMID: 35437792
Background: Juvenile-onset Huntington's disease (JOHD) is a rare and particularly devastating form of Huntington's disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking. Neurofilament light...
9.
Rodrigues F, Owen G, Sathe S, Pak E, Kaur D, Ehrhardt A, et al.
J Huntingtons Dis
. 2022 Mar;
11(1):59-69.
PMID: 35253773
Background: Biomarkers are needed to monitor disease progression, target engagement and efficacy in Huntington's disease (HD). Cerebrospinal fluid (CSF) is an ideal medium to research such biomarkers due to its...
10.
Ferreira J, Rodrigues F, Duarte G, Mestre T, Bachoud-Levi A, Bentivoglio A, et al.
Mov Disord
. 2021 Nov;
37(1):25-35.
PMID: 34842303
Background: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. Its management is challenging, consisting mainly of off-label treatments. Objectives: The International Parkinson and Movement Disorder Society...